DDRE-26. TARGETING THE UNFOLDED PROTEIN RESPONSE POTENTIATES MARIZOMIB ANTITUMOR ACTIVITY IN GLIOBLASTOMA

Glioblastoma (GBM) is the most prevalent and aggressive malignant tumor of the central nervous system in adults. Patients with GBM have a poor prognosis, with a median survival of 15 months with current standard-of-care treatment, consisting of surgery followed by radiotherapy with concomitant and a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Severin, Christophe, Benitez-Hernandez, Jorge, Dumitru, C Dan, Beltran-Raygoza, Nishdallyh, Flandin-Blety, Pierre, Escoubet, Laure, Rolfe, Mark
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Drug Discovery, Drug Resistance
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650415/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.271
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia